Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy National Research Corporation (NRC) stocks in Canada

Learn how to easily invest in National Research Corporation stocks.

National Research Corporation is a diagnostics & research business based in the US. National Research Corporation stocks (NRC.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $47.25 – a decrease of 6.26% over the previous week. National Research Corporation employs 485 staff and has a trailing 12-month revenue of around $144.4 million.

How to buy shares in National Research Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NRC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy National Research Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted National Research Corporation's stock price?

Since the stock market crash in March caused by coronavirus, National Research Corporation's stock price has had significant negative movement.

Its last market close was $38.21, which is 43.63% down on its pre-crash value of $67.79 and 12.38% up on the lowest point reached during the March crash when the stocks fell as low as $34.

If you had bought $1,000 worth of National Research Corporation stocks at the start of February 2020, those stocks would have been worth $584.12 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $549.46.

National Research Corporation stock price (NASDAQ:NRC)

Use our graph to track the performance of NRC stocks over time.

National Research Corporation shares at a glance

Information last updated 2022-01-10.
Latest market close$38.21
52-week range$39.16 - $55.36
50-day moving average $43.41
200-day moving average $46.98
Wall St. target priceN/A
PE ratio 29.1143
Dividend yield $0.36 (1.18%)
Earnings per share (TTM) $1.40

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Feature Table description
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks (total value up to $9,000) when you deposit and trade $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of at least $200/month. Valid until March 1, 2022.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

National Research Corporation price performance over time

Historical closes compared with the close of $38.21 from 2022-01-14

1 week (2022-01-07) -6.26%
1 month (2021-12-16) -9.52%
3 months (2021-10-15) -10.89%
6 months (2021-07-16) -24.50%
1 year (2021-01-15) -18.04%
2 years (2020-01-16) -42.81%
3 years (2019-01-16) 38.99
5 years (2017-01-13) 105.98%

Is National Research Corporation under- or over-valued?

Valuing National Research Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of National Research Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

National Research Corporation's P/E ratio

National Research Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 29x. In other words, National Research Corporation shares trade at around 29x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

National Research Corporation's EBITDA

National Research Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $55.6 million.

The EBITDA is a measure of a National Research Corporation's overall financial performance and is widely used to measure a its profitability.

National Research Corporation financials

Revenue TTM $144.4 million
Operating margin TTM 33.75%
Gross profit TTM $84.1 million
Return on assets TTM 21.5%
Return on equity TTM 51.55%
Profit margin 24.96%
Book value $3.27
Market capitalisation $1 billion

TTM: trailing 12 months

National Research Corporation share dividends


Dividend payout ratio: 32.74% of net profits

Recently National Research Corporation has paid out, on average, around 32.74% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.18% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), National Research Corporation shareholders could enjoy a 1.18% return on their shares, in the form of dividend payments. In National Research Corporation's case, that would currently equate to about $0.36 per share.

While National Research Corporation's payout ratio might seem fairly standard, it's worth remembering that National Research Corporation may be investing much of the rest of its net profits in future growth.

National Research Corporation's most recent dividend payout was on 13 January 2022. The latest dividend was paid out to all shareholders who bought their shares by 28 December 2021 (the "ex-dividend date").

National Research Corporation share price volatility

Over the last 12 months, National Research Corporation's shares have ranged in value from as little as $39.1589 up to $55.36. A popular way to gauge a stock's volatility is its "beta".

NRC.US volatility(beta: 0.73)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while National Research Corporation's is 0.7288. This would suggest that National Research Corporation's shares are less volatile than average (for this exchange).

National Research Corporation overview

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site